ERG and SIM2 transcription factors in prostate cancer – their role in carcinogenesis and potential clinical utility
Has parts
Paper I: International Journal of Oncology 30(1), Rostad, K.; Mannelqvist, M.; Halvorsen, O. J.; Øyan, A. M.; Bø, T. H.; Stordrange, L.; Olsen, S.; Haukaas, S. A.; Lin, B.; Hood, L.; Jonassen, I.; Akselen, L. A.; Kalland, K. H., ERG upregulation and related ETS transcription factors in prostate cancer, pp. 19-32. Published by Spandidos Publications. Reproduced with permission. Published version.Paper II: Clinical Cancer Research 13(3), Halvorsen, O. J.; Rostad, K.; Øyan, A. M.; Puntervoll, H.; Bø, T. H.; Stordrange, L.; Olsen, S.; Haukaas, S. A.; Hood, L.; Jonassen, I.; Kalland, K. H.; Akslen, L. A., Increased expression of SIM2-s protein is a novel marker of aggressive prostate cancer, pp. 892-897. Copyright 2007 American Association for Cancer Research. Full text not available in BORA due to publisher restrictions. The published version is available at: http://dx.doi.org/10.1158/1078-0432.CCR-06-1207
Paper III: APMIS 117(8), Rostad, K.; Hellwinkel, O. J. C.; Haukaas, S. A.; Halvorsen, O. J.; Øyan, A. M.; Haese, A.; Budäus, L.; Albrecht, H.; Akslen, L. A.; Schlomm, T.; Kalland, K. H., TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favourable prognosis, pp. 575-582. Copyright 2009 The Authors, Journal Compilation 2009 APMIS. Full text not available in BORA due to publisher restrictions. The published version is available at: http://dx.doi.org/10.1111/j.1600-0463.2009.02517.x
Publisher
The University of BergenCopyright
Copyright the author. All rights reservedThe author